Serum proteomic-based analysis identifying autoantibody against ENO1 as a potential diagnostic biomarker in nasopharyngeal carcinoma

doi:10.3760/cma.j.cn371439-20191223-00069

Abstract

Abstract:

Objective To screen and identify autoantibody biomarker to diagnose patients with nasopharyngeal carcinoma (NPC). Methods Candidate autoantibodies against tumor-associated antigens were identified from NPC CNE2 cells using serological proteome analysis. Levels of candidate autoantibody biomarkers were measured by enzyme-linked immunosorbent assay (ELISA) in 50 patients with NPC and 80 normal controls recruited from the Cancer Hospital of Shantou University Medical College between July 2014 and January 2015. Receiver operating characteristic curve (ROC) was employed to evaluate diagnostic efficacy. Results Serological proteome analysis showed that sera from patients with NPC yielded a positive spot, of which was identified as enolase 1 (ENO1). ELISA results showed that the level of serum autoantibody against ENO1 in patients with NPC was significantly higher than that in normal controls [0.165 (0.088, 0.378) vs. 0.100 (0.054, 0.117), Z=4.077, P<0.001]. With the optimum diagnostic cutoff of 0.164, ROC curve showed the diagnostic sensitivity and specificity of autoantibodies against ENO1 were 52.0% and 90.0%, respectively. Measurement of autoantibody against ENO1 demonstrated a positive rate of 75.0% for early stage NPC. Conclusion Autoantibody against ENO1 may be a potential diagnostic biomarker for NPC.

Key words: Esophageal neoplasms, Early diagnosis, Autoantibody, Serological proteome analysis technique, Enolase 1

Zhan Xiaofen, Weng Xuefen, Yang Shihuang, Xu Yiwei, Peng Yuhui, Guo Hong. Serum proteomic-based analysis identifying autoantibody against ENO1 as a potential diagnostic biomarker in nasopharyngeal carcinoma[J]. Journal of International Oncology, 2020, 47(9): 513-517.

Figures/Tables 4

References 18

[1]	Chua MLK, Wee JTS, Hui EP, et al. Nasopharyngeal carcinoma[J]. Lancet, 2016,387(10022):1012-1024. DOI: 10.1016/S0140-6736(15)00055-0. doi: 10.1016/S0140-6736(15)00055-0 pmid: 26321262
[2]	曹新平, 卢泰祥, 叶伟军, 等. Ⅰ、Ⅱ期鼻咽癌外照射加腔内放疗远期疗效的前瞻性研究[J]. 癌症, 2007,26(2):204-207. DOI: 10.3969/j.issn.1000-467X.2007.02.019.
[3]	Chen Y, Sun Y, Liang SB, et al. Progress report of a randomized trial comparing long-term survival and late toxicity of concurrent chemoradiotherapy with adjuvant chemotherapy versus radiotherapy alone in patients with stage Ⅲ to ⅣB nasopharyngeal carcinoma from endemic regions of China[J]. Cancer, 2013,119(12):2230-2238. DOI: 10.1002/cncr.28049. doi: 10.1002/cncr.28049 pmid: 23576020
[4]	Yip TT, Ngan RK, Fong AH, et al. Application of circulating plasma/serum EBV DNA in the clinical management of nasopharyngeal carcinoma[J]. Oral Oncol, 2014,50(6):527-538. DOI: 10.1016/j.oraloncology.2013.12.011. doi: 10.1016/j.oraloncology.2013.12.011
[5]	Lin LH, Xu YW, Huang LS, et al. Serum proteomic?based analysis identifying autoantibodies against PRDX2 and PRDX3 as potential diagnostic biomarkers in nasopharyngeal carcinoma[J]. Clin Proteom, 2017,14:6. DOI: 10.1186/s12014-017-9141-5. doi: 10.1186/s12014-017-9141-5
[6]	Qiu J, Choi G, Li L, et al. Occurrence of autoantibodies to annexin Ⅰ, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera[J]. J Clin Oncol, 2008,26(31):5060-5066. DOI: 10.1200/JCO.2008.16.2388. doi: 10.1200/JCO.2008.16.2388 pmid: 18794547
[7]	Qin J, Zeng N, Yang T, et al. Diagnostic value of autoantibodies in lung cancer: a systematic review and meta-analysis[J]. Cell Physiol Biochem, 2018,51(6):2631-2646. DOI: 10.1159/000495935. doi: 10.1159/000495935 pmid: 30562746
[8]	Jett JR, Peek LJ, Fredericks L, et al. Audit of the autoantibody test, EarlyCDT-Lung, in 1600 patients: an evaluation of its performance in routine clinical practice[J]. Lung Cancer, 2014,83(1):51-55. DOI: 10.1016/j.lungcan.2013.10.008. doi: 10.1016/j.lungcan.2013.10.008
[9]	Sullivan FM, Farmer E, Mair FS, et al. Detection in blood of autoantibodies to tumour antigens as a case-finding method in lung cancer using the EarlyCDT-Lung Test (ECLS): study protocol for a randomized controlled trial[J]. BMC Cancer, 2017,17(1):187. DOI: 10.1186/s12885-017-3175-y. doi: 10.1186/s12885-017-3175-y pmid: 28284200
[10]	Peng YH, Xu YW, Huang LS, et al. Autoantibody signatures combined with Epstein-Barr virus capsid antigen-IgA as a biomarker panel for the detection of nasopharyngeal carcinoma[J]. Cancer Prev Res, 2015,8(8):729-736. DOI: 10.1158/1940-6207.CAPR-14-0397. doi: 10.1158/1940-6207.CAPR-14-0397
[11]	Desmetz C, Mange A, Maudelonde T, et al. Autoantibody signatures: progress and perspectives for early cancer detection[J]. J Cell Mol Med, 2011,15(10):2013-2024. DOI: 10.1111/j.1582-4934.2011.01355.x. doi: 10.1111/j.1582-4934.2011.01355.x
[12]	Trojanowicz B, Winkler A, Hammje K, et al. Retinoic acid-mediated down-regulation of ENO1/MBP-1 gene products caused decreased invasiveness of the follicular thyroid carcinoma cell lines[J]. J Mol Endocrinol, 2009,42(3):249-260. DOI: 10.1677/JME-08-0118. doi: 10.1677/JME-08-0118 pmid: 19060179
[13]	Fu QF, Liu Y, Fan Y, et al. Alpha-enolase promotes cell glycolysis, growth, migration, and invasion in non-small cell lung cancer through FAK-mediated PI3K/AKT pathway[J]. J Hematol Oncol, 2015,8(1):22. DOI: 10.1186/s13045-015-0117-5. doi: 10.1186/s13045-015-0117-5
[14]	Zhu W, Li H, Yu Y, et al. Enolase-1 serves as a biomarker of diagnosis and prognosis in hepatocellular carcinoma patients[J]. Cancer Manag Res, 2018,10:5735-5745. DOI: 10.2147/CMAR.S182183. doi: 10.2147/CMAR.S182183 pmid: 30532594
[15]	Zhang L, Wang H, Dong X. Diagnostic value of α-enolase expression and serum α-enolase autoantibody levels in lung cancer[J]. J Bras Pneumol, 2018,44(1):18-23. DOI: 10.1590/S1806-37562016000000241. doi: 10.1590/S1806-37562016000000241 pmid: 29538538
[16]	程超, 龙孝斌, 李欣, 等. α-烯醇化酶在鼻咽癌中的表达[J]. 临床耳鼻咽喉头颈外科杂志, 2011,25(12):554-556. DOI: 10.3969/j.issn.1001-1781.2011.12.009.
[17]	Liu Z, Chen C, Yang H, et al. Proteomic features of potential tumor suppressor NESG1 in nasopharyngeal carcinoma[J]. Proteomics, 2012,12(22):3416-3425. DOI: 10.1002/pmic.201200146. doi: 10.1002/pmic.201200146
[18]	Rucksaken R, Pairojkul C, Pinlaor P, et al. Plasma autoantibodies against heat shock protein 70, enolase 1 and ribonuclease/angiogenin inhibitor 1 as potential biomarkers for cholangiocarcinoma[J]. PLoS One, 2014,9(7):e103259. DOI: 10.1371/journal.pone.0103259. doi: 10.1371/journal.pone.0103259 pmid: 25058392

临床病理特征	例数	阳性(%)	χ²值	P值
性别
男	38	21(55.3)	0.675	0.411
女	12	5(41.7)
年龄(岁)
≤50	21	13(61.9)	1.423	0.233
>50	29	13(44.8)
T分期
T_1-2	21	14(66.7)	3.120	0.077
T_3-4	29	12(41.4)
N分期
N_0-1	23	13(64.3)	0.349	0.555
N_2-3	27	13(57.1)
TNM分期
Ⅱ期	8	6(76.2)	1.071	0.301
Ⅲ~Ⅳ期	42	20(47.6)